Sanofi-Aventis to produce shikimic acid for Roche's Tamiflu

By Angela McDaniels

Seattle, March 16 - Sanofi-Aventis has signed an agreement with Roche to produce shikimic acid for Roche's Tamiflu supply chain, according to a company news release.

Shikimic acid is the key raw material for the manufacture of oseltamivir, Tamiflu's active ingredient. Under the terms of the agreement, Sanofi-Aventis will supply the acid to Roche exclusively.

Paris-based Sanofi-Aventis develops pharmaceutical products in major therapeutic areas including cardiovascular, thrombosis, oncology, metabolic diseases and vaccines.

Roche is headquartered in Basel, Switzerland, and develops pharmaceuticals and diagnostics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.